News

Daiichi Sankyo R&D Division Oncology Function head, executive officer Koichi Akahane said: "There are no HER2-targeting treatment options currently available for patients with HER2-positive gastric cancer whose tumors

This decision followed a planned interim analysis by an independent Data Monitoring Committee (DMC) of unblinded efficacy and safety data from the first 65 patients from the ongoing

Pedmark, a formulation of sodium thiosulfate (STS), is a water-soluble thiol compound that serves as a chemical reducing agent. Delayed administration (between four to eight hours) of high dose

In 2015, the consumer healthcare JV was established, as part of a three-part inter-conditional transaction between GSK and Novartis. The JV is a combination of Novartis' over-the-counter (OTC)

The round was oversubscribed. Adagene CEO Peter Luo said: "Adagene is built on a proprietary discovery engine that we have leveraged to discover highly differentiated portfolio of agonist

Breakthrough Therapy Designation is a process designed to expedite the development and review of drugs that are intended to treat a serious or life-threatening condition. It is based

Vobarilizumab is the firm’s anti-IL-6R Nanobody, which did not achieve the primary endpoint of dose response based on the modified BILAG-based combined lupus assessment (mBICLA) at week 24.

RiVax has previously been granted orphan drug designation from the US Food and Drug Administration (FDA). The European Commission grants orphan designations for medicines that treat a life-threatening

The companies undertake a wide range of operations to make clinical trials more efficient overall, using Hitachi's advanced digital technology such as AI, aiming to shorten the period